Journal
CANCER DISCOVERY
Volume 10, Issue 8, Pages 1097-1099Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-20-0786
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Cancer Discovery, Diab and colleagues demonstrate in a phase I trial enrolling 38 patients diagnosed with advanced solid tumors that combining the pegylated IL2 bempegaldesleukin with an anti-PD-1 mAb is safe, with an overall response rate of 59.5%. This compelling clinical activity is supported by the potent immune proliferation and activation of circulating T and natural killer cells with a >4-fold increase in the CD8/regulatory T-cell ratio in tumors, independent of baseline PD-L1 expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available